TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven, resectable squamous epithelial carcinoma of the oropharynx and the cavity of the mouth~2. R0-resection possible~3. All T N2 M0 / all T N3 M0 / if T3 or T4a also N0-1 M0~4. Leucocytes \> 4000/mm³ bzw. neutrophils \> 2000/mm³, thrombocytes \> 100000/mm³~5. adequate kidney function, defined as serum creatinine und urea in normal range, Creatinine clearance \> 60 ml/min~6. adequate liver function with glutamate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT) and bilirubin in normal range~7. electrolytes in normal range~8. risks of anesthesia complications normal or minor increased~9. Eastern Cooperative Oncology Group (ECOG) 0-2 / Karnofsky \>= 60%~10. Age 18 - 80 years~11. signed written informed consent~12. effective contraception for both male and female subjects if the risk of conception exists~    Exclusion Criteria:~13. T1 N0 M0 / T1 N1 M0 / T2 N0 M0 / T2 N1 M0~14. Resection without curative intention: primary tumor is not treatable with resection methods~15. Infiltration of the lower jaw~16. M1 status~17. Tumor not measurable with Innovation Center Computer Assisted Surgery (ICCAS) methods~18. No prior chemotherapy or radiation (a primary surgery is allowed)~19. Metachronous or oder synchronous malignoma (Exception: basal cell carcinoma)~20. Life expectance \< 3 months~21. ECOG \> 2; Karnofsky \< 60%~22. acute infections or fever~23. known HIV-infection or other immune suppression~24. severe cardio pulmonary concomitant diseases~25. chronic disease with continuous therapy (uncontrolled diabetes, rheumatoid arthritis) especially continuous therapy with steroids~26. other concomitant diseases which, in the investigator's opinion, would exclude the patient from the study~27. Contraindications which permit a therapy with Docetaxel, Cisplatin, 5-FU or radiation therapy~28. missing patient's compliance~29. regular Follow-up visits not possible~30. Pregnancy or lactation period~31. legal incapacity or limited legal capacity~32. Participation in another clinical trial or administration of a not approved substance within 30 days before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU) (Type: EXPERIMENTAL): Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Administration of ALA vs Progesterone for the Subchorionic Hematoma Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 24-37~* Gestational week: 7- 12~* Evidence of threatened miscarriage (pelvic pain with or without vaginal bleeding)~* Ultrasound evidence of subchorionic hematoma~Exclusion Criteria:~* Lack of fetus~* Absence of fetal heart tone~* Uterine anomaly or fetal anomaly~* Presence of multiple pregnancy~* Gestation pathology~* Therapies with anti-coagulants or anti-hypertensive drugs

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Lipoic acid (Type: EXPERIMENTAL): vaginal capsules of lipoic acid (10 mg, one capsule per day)
- Progesterone (Type: ACTIVE_COMPARATOR): Vaginal soft gel of progesterone (200 mg, two capsules per day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive. ALK positivity must have been determined by a validated fluorescence in situ hybridization (FISH) test (recommended probe, Vysis ALK Break-Apart Probe) or a validated immunohistochemistry (IHC) test (recommended antibody, clone D5F3)~* Participant had received two prior systemic lines of therapy, which must have included one line of platinum-based chemotherapy and one line of crizotinib~* Prior CNS or leptomeningeal metastases allowed if asymptomatic~* Participants with symptomatic CNS metastases for whom radiotherapy is not an option will be allowed to participate in this study~* Measurable disease by RECIST Version 1.1 prior to the administration of study treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment~Exclusion Criteria:~* Participants with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal \[GI\] cancer by endoscopic resection or in situ carcinoma of the cervix)~* Participants who have received any previous ALK inhibitor other than crizotinib~* Any GI disorder that may affect absorption of oral medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alectinib (Type: EXPERIMENTAL): Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Premetrexed/Docetaxel (Type: ACTIVE_COMPARATOR): Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter \[mg/m\^2\] of body surface area) or docetaxel (75 mg/m\^2) intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Stature Related Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1 Segment 1 :Boys at the age range of 8-13 years 2. Segment 2: Boys at the age range of 12-17 years 3. Tanner stage 1 (segment 1 only) 4. more than 2 SD's (standard deviation) below the average height~Exclusion Criteria:~1. Mental retardation,~2. Psychiatric illness,~3. Lack of informed consent\\assent.~4. Health status that required chronic treatment with steroids

- Gender: MALE
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- GH treatment (Type: EXPERIMENTAL): 4 years of GH treatment
- Placebo (Type: PLACEBO_COMPARATOR): 1 year treatment with placebo followed by optional 3 years of GH treatment
- Non treatment group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* percapillary pulmonary hypertension diagnosed by right heart catheterisation -- stable therapy and clinical condition for at least 4 weeks~* sleep disordered breathing with apnea/hypopnea index \> 10 events/h and/or median nocturnal oxygen saturation \<90%~Exclusion criteria:~* Pregnancy~* severe daytime hypoxemia (PaO2 \< 7.2 kPA)~* patients with predominantly obstructive sleep apnea.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- acetazolamide (Type: EXPERIMENTAL): 1 week therapy, cross-over design
- Placebo tablet (Type: PLACEBO_COMPARATOR): One week, cross-over design
- supplemental oxygen during nights (Type: EXPERIMENTAL): One week, cross-over design
- Non-invasive ventilation (Type: EXPERIMENTAL): One week, cross-over design
- room air (Type: SHAM_COMPARATOR): room air applied via sham-oxygen-concentrator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vilazodone in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-70 years of age.~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder.~* The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration.~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for:~  * Any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode~ * Any depressive episode with psychotic or catatonic features~ * Panic disorder with or without agoraphobia~ * Obsessive-compulsive disorder~ * Schizophrenia, schizoaffective, or other psychotic disorder~ * Bulimia or anorexia nervosa~ * Presence of borderline personality disorder or antisocial personality disorder~ * Mental retardation, dementia, amnesia, or other cognitive disorders.~* Patients who are considered a suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
- Vilazodone 20 mg/day (Type: EXPERIMENTAL): Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
- Vilazodone 40 mg/day (Type: EXPERIMENTAL): Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
- Citalopram 40 mg/day (Type: ACTIVE_COMPARATOR): Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult and adolescents (≥12 years to \<18 years, and weighing ≥40 kg).~2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit.~3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.~4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit~5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.~6. History of inadequate response to treatment with topical medications.~Exclusion Criteria:~1. Participation in a prior lebrikizumab clinical study.~2. Treatment with the following prior to the baseline visit:~   1. An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer.~  2. Dupilumab within 8 weeks.~  3. B-cell-depleting biologics, including to rituximab, within 6 months.~  4. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.~3. Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.~4. Uncontrolled chronic disease that might require bursts of oral corticosteroids.~5. Evidence of active acute or chronic hepatitis~6. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~7. History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lebrikizumab + Topical Corticosteroid (Type: EXPERIMENTAL): 500 mg Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of 250 mg Lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14.~Topical corticosteroid (TCS) will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response.
- Placebo + Topical Corticosteroid (Type: PLACEBO_COMPARATOR): Two placebo subcutaneous (SC) injections as a loading dose at Baseline and Week 2 followed by a single injection of placebo every Q2W from Week 4 until Week 14.~TCS will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease~* More than 5% blasts in bone marrow~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Life expectancy of ≥ 12 weeks~Exclusion Criteria:~* History or presence of clinically relevant central nervous system (CNS) pathology~* Infiltration of cerebrospinal fluid (CSF) by ALL~* Autologous/allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment~* Active Graft-versus-Host Disease (GvHD)~* Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib~* Cancer chemotherapy within two weeks prior to start of blinatumomab treatment~* Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment~* Infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)~* Pregnant or nursing women~* Previous treatment with blinatumomab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab 15 μg (Type: EXPERIMENTAL): Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
- Blinatumomab 5/15 μg (Type: EXPERIMENTAL): Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
- Blinatumomab 5/15/30 μg (Type: EXPERIMENTAL): Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are overtly healthy males or females, as determined through medical history and physical examination.~* Possess a valid driver's license and is an active driver at screening. Driven a minimum of 8,000 miles (about 13,000 kilometers) per year for the preceding 3 years.~* Have a score of \<10 on the Epworth Sleepiness Scale.~Exclusion Criteria:~* Have a history within 3 months of admission, or current treatment for, a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep.~* Have a history of difficulty either falling asleep or staying asleep in the previous 3 months of admission that is considered clinically significant by the investigator.~* Are expected to use any other medication or dietary supplement to promote sleep including over the-counter sleep medications, during their participation in the study.~* Have traveled across 2 or more time zones (transmeridian travel) in the past 2 weeks prior to randomization.~* Have worked in a night shift in the past 2 weeks prior to randomization.~* Show a history of central nervous system (CNS) conditions such as strokes, transient ischemic attacks, significant head trauma, seizures, CNS infections, migraine, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study.~* Show evidence of significant active neuropsychiatric disease (e.g., manic depressive illness, schizophrenia, depression) considered as clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally in one of four study periods.
- 100 milligrams (mg) Lasmiditan (Type: EXPERIMENTAL): 100 mg lasmiditan administered orally in one of four study periods.
- 200 mg Lasmiditan (Type: EXPERIMENTAL): 200 mg lasmiditan administered orally in one of four study periods.
- Diphenhydramine (Type: ACTIVE_COMPARATOR): 50 mg diphenhydramine administered orally in one of four study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes~2. HbA1c \> 6.5%~3. age \> 18 years~4. male and females~Exclusion Criteria:~1. age \> 75 years~2. HbA1c \> 10 %,~3. reduced renal function (eGFR \< 60 ml/min/1.73 m²).~4. insulin therapy, or any antidiabetic medication other than metformin.~5. uncontrolled hypertension (\> 180/\>110 mmHg)~6. cardiovascular event within the last 3 months~7. Use of loop diuretics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: ACTIVE_COMPARATOR): Dapagliflozin, 10 mg/day, oral administration, 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete